Alina Kline‑Schoder
Founder & CEO or …
Neo Splice Therapeutics
Neo Splice Therapeutics provides NeoSplice™, an AI-driven platform that expands the pool of druggable targets by analyzing large biological datasets and validating candidates experimentally. The company offers end‑to‑end R&D services and partnership options for pharma and biotech firms to access and co‑develop these novel targets.
- Artificial Intelligence
- Biotechnology
Updated 6 months ago
Funding
Funding rounds are not available yet.
Founders
Gloria Sheynkman
Founder
Product
Problem
Traditional drug discovery pipelines often miss many potential therapeutic targets because they rely on limited experimental screens and conventional computational methods, leading to a narrow pool of druggable candidates for diseases with high unmet medical need.
Solution
Neo Splice Therapeutics offers NeoSplice™, an AI-powered platform that dramatically expands the universe of druggable targets. By integrating advanced computational models with experimental biology, the platform identifies orders of magnitude more candidate targets than traditional approaches. The system prioritizes novel targets that are overlooked by conventional methods, enabling the development of new therapeutic programs. Neo Splice also provides R&D services to translate these discoveries into viable drug development projects, and actively seeks partnerships with pharmaceutical and biotechnology companies to co‑develop promising candidates.
Target Audience
Primary customers are pharmaceutical and biotechnology companies seeking to broaden their target portfolios and accelerate early‑stage drug discovery for high‑need disease areas.
Features
- AI-driven computational engine that screens vast biological datasets to uncover previously unrecognized therapeutic targets
- Integration of machine learning predictions with experimental validation workflows to ensure target relevance and druggability
- Scalable pipeline capable of generating a significantly larger pool of candidate targets compared to conventional discovery methods
- End‑to‑end R&D service offering from target identification through preclinical validation
- Partnership model that allows pharma and biotech firms to access proprietary target lists and co‑develop programs